1. LINC02381-ceRNA exerts its oncogenic effect through regulation of IGF1R signaling pathway in glioma

   • Hossein Nemati
   • Masoumeh Fakhre-Taha
   • Bahram M. Soltani

   Laboratory Investigation 23 April 2022 Pages: 1 - 13

   

2. The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma

   • Julia Klingenschmid
   • Aleksandrs Krigers
   • Christian F. Freyschlag

   Clinical Study Open access 25 April 2022 Pages: 15 - 22

   

3. High dose image-guided, intensity modulated radiation therapy (IG-IMRT) for chordomas of the sacrum, mobile spine and skull base: preliminary outcomes

   • Andre Tsin Chih Chen
   • Carlos Bo Chur Hong
   • William Gemio Jacobsen Teixeira

   Research 22 April 2022 Pages: 23 - 31

   

4. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors

   • Andrew B. DeAtkine
   • Moaaz Abdelrashid
   • L. Burt Nabors

   Clinical Study 20 April 2022 Pages: 33 - 40

   

5. Effect of distance from target on hypopituitarism after stereotactic radiosurgery for pituitary adenomas

   • Natasha Ironside
   • Harrison Snyder
   • Jason P. Sheehan

   Clinical Study 24 April 2022 Pages: 41 - 50

   

6. The Clinical Frailty Scale as useful tool in patients with brain metastases

   • Johannes Kerschbaumer
   • Aleksandrs Krigers
   • Christian F. Freyschlag

   Research Open access 13 April 2022 Pages: 51 - 57

   

7. Preoperative antiepileptic drug prophylaxis for early postoperative seizures in supratentorial meningioma: a single-center experience

   • Qing Cai
   • Yingxi Wu
   • Dayun Feng

   Research 17 April 2022 Pages: 59 - 67

   

8. Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologists

   • Leah E. Walsh
   • Laura C. Polacek
   • Eli L. Diamond

   Research 18 April 2022 Pages: 69 - 79

9. LIM and SH3 protein 1 (LASP1) differentiates malignant chordomas from less malignant chondrosarcomas

   • Cas Vanderheijden
   • Thomas Vaessen
   • Govert Hoogland

   Laboratory Investigation Open access 04 May 2022 Pages: 81 - 88

   

10. Comparison of the quality of death between primary malignant brain tumor patients and other cancer patients: results from a nationwide bereavement survey in Japan

    • Maho Aoyama
    • Kento Masukawa
    • Mitsunori Miyashita

    Research 18 April 2022 Pages: 89 - 97

11. Primary CNS lymphoma of the corpus callosum: presentation and neurocognitive outcomes

    • Christelle Nilles
    • Daniel Delgadillo
    • Caroline Houillier

    Research 21 April 2022 Pages: 99 - 109

    

12. Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients

    • Vasileios K. Kavouridis
    • Keith L. Ligon
    • J. Bryan Iorgulescu

    Clinical Study 26 April 2022 Pages: 111 - 116

    

13. Predictors of survival and time to progression following operative management of intramedullary spinal cord astrocytomas

    • Andrew M. Hersh
    • Albert Antar
    • Daniel M. Sciubba

    Research 11 May 2022 Pages: 117 - 127

    

14. Correction to: Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma

    • Naiyuan Shao
    • Jiahao Mao
    • Qing Lan

    Correction Open access 04 May 2022 Pages: 129 - 129